https://orcid.org/0000-0002-4788-5729
References
- Di Battista M, Barsotti S, Orlandi M, Lepri G, Codullo V, Della Rossa A, et al. One year in review 2021: systemic sclerosis. Clin Exp Rheumatol 2021;39:3–12.
- Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017;76:1327–39.
- Barsotti S, Lorenzoni V, Di Battista M, D’Ascanio A, Silvia B, Puccetti L, et al. Prostanoids in scleroderma microangiopathy: clinical and pharmacoeconomic comparison between two intravenous regimens. Scand J Rheumatol 2021;50:307–13.
- Cutolo M, Smith V. Detection of microvascular changes in systemic sclerosis and other rheumatic diseases. Nat Rev Rheumatol 2021;17:665–77.
- Cutolo M, Vanhaecke A, Ruaro B, Deschepper E, Ickinger C, Melsens K, et al. Is laser speckle contrast analysis (LASCA) the new kid on the block in systemic sclerosis? A systematic literature review and pilot study to evaluate reliability of LASCA to measure peripheral blood perfusion in scleroderma patients. Autoimmun Rev 2018;17:775–80.
- Van Den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013;2013:2737–47.
- Ingegnoli F, Schioppo T, Allanore Y, Caporali R, Colaci M, Distler O, et al. Practical suggestions on intravenous iloprost in Raynaud’s phenomenon and digital ulcer secondary to systemic sclerosis: systematic literature review and expert consensus. Semin Arthritis Rheum 2019;48:686–93.
- Negrini S, Magnani O, Matucci-Cerinic M, Carignola R, Data V, Montabone E, et al. Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study. Clin Exp Med 2019;19:357–66.
- Pauling JD, Hackett N, Guida A, Merkel PA. Performance of laser-derived imaging for assessing digital perfusion in clinical trials of systemic sclerosis-related digital vasculopathy: a systematic literature review. Semin Arthritis Rheum 2020;50:1114–30.
- Trombetta AC, Pizzorni C, Ruaro B, Paolino S, Sulli A, Smith V, et al. Effects of longterm treatment with bosentan and iloprost on nailfold absolute capillary number, fingertip blood perfusion, and clinical status in systemic sclerosis. J Rheumatol 2016;43:2033–41.
- Rotondo C, Nivuori M, Chialà A, Praino E, Matucci Cerinic M, Cutolo M, et al. Evidence for increase in finger blood flow, evaluated by laser Doppler flowmetry, following iloprost infusion in patients with systemic sclerosis: a week-long observational longitudinal study. Scand J Rheumatol 2018;47:311–8.
- Grant SM, Goa KL. Iloprost: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 1992;43:889–924.
- Balbir-Gurman A, Braun-Moscovici Y, Livshitz V, Schapira D, Markovits D, Rozin A, et al. Antioxidant status after iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis. Clin Rheumatol 2007;26:1517–21.
- Tsou PS, Palisoc PJ, Flavahan NA, Khanna D. Dissecting the cellular mechanism of prostacyclin analog iloprost in reversing vascular dysfunction in scleroderma. Arthritis Rheumatol 2021;73:520–9.